WO2026044228A1 - Compositions de métabolites de la voie biologique du chorismate de et leurs méthodes d'utilisation - Google Patents

Compositions de métabolites de la voie biologique du chorismate de et leurs méthodes d'utilisation

Info

Publication number
WO2026044228A1
WO2026044228A1 PCT/US2025/043182 US2025043182W WO2026044228A1 WO 2026044228 A1 WO2026044228 A1 WO 2026044228A1 US 2025043182 W US2025043182 W US 2025043182W WO 2026044228 A1 WO2026044228 A1 WO 2026044228A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
chorismate
subject
core
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/043182
Other languages
English (en)
Inventor
Dong KONG
Robert Hardie MILLS
Paul Francis MILLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Piton Therapeutics Inc
Original Assignee
Piton Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piton Therapeutics Inc filed Critical Piton Therapeutics Inc
Publication of WO2026044228A1 publication Critical patent/WO2026044228A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des compositions (p. ex. des compositions pharmaceutiques, des compositions nutraceutiques) et des procédés utiles pour, entre autres choses, moduler des niveaux de certains métabolites du chorismate chez un sujet (p. ex. dans l'intestin d'un sujet). La modulation des niveaux de certains métabolites du chorismate chez un sujet (p. ex. les niveaux des métabolites du chorismate dans l'intestin) peut avoir des effets bénéfiques, prophylactiques et/ou thérapeutiques pour le sujet, par exemple, en améliorant la fonction cognitive ou en traitant un ou plusieurs signes ou symptômes d'un trouble neurologique.
PCT/US2025/043182 2024-08-23 2025-08-22 Compositions de métabolites de la voie biologique du chorismate de et leurs méthodes d'utilisation Pending WO2026044228A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202463686692P 2024-08-23 2024-08-23
US63/686,692 2024-08-23

Publications (1)

Publication Number Publication Date
WO2026044228A1 true WO2026044228A1 (fr) 2026-02-26

Family

ID=98865645

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/043182 Pending WO2026044228A1 (fr) 2024-08-23 2025-08-22 Compositions de métabolites de la voie biologique du chorismate de et leurs méthodes d'utilisation

Country Status (1)

Country Link
WO (1) WO2026044228A1 (fr)

Similar Documents

Publication Publication Date Title
Xie et al. Oral treatment with Lactobacillus reuteri attenuates depressive-like behaviors and serotonin metabolism alterations induced by chronic social defeat stress
Zhao et al. Saturated long-chain fatty acid-producing bacteria contribute to enhanced colonic motility in rats
Ding et al. A next-generation probiotic: Akkermansia muciniphila ameliorates chronic stress–induced depressive-like behavior in mice by regulating gut microbiota and metabolites
Cheng et al. Lactobacillus paracasei PS23 improves cognitive deficits via modulating the hippocampal gene expression and the gut microbiota in D-galactose-induced aging mice
Cui et al. Modulation of the gut microbiota by the mixture of fish oil and krill oil in high-fat diet-induced obesity mice
El Aidy et al. Microbiome to brain: unravelling the multidirectional axes of communication
TWI787272B (zh) 包含細菌菌株之組合物
Mu et al. Probiotics counteract hepatic steatosis caused by ketogenic diet and upregulate AMPK signaling in a model of infantile epilepsy
Legan et al. Tryptophan‐synthesizing bacteria enhance colonic motility
EP4108260A1 (fr) Composition pour soulager l'hypertension pulmonaire, procédé de prédiction du pronostic de l'hypertension pulmonaire, procédé d'aide à la détermination de la gravité de l'hypertension pulmonaire, et procédé d'aide au diagnostic de l'hypertension pulmonaire
CN115003318A (zh) 包含细菌菌株的组合物
TW201907927A (zh) 包含細菌菌株之組合物
Cai et al. Lactobacillus johnsonii GLJ001 prevents DSS-induced colitis in mice by inhibiting M1 macrophage polarization via gut microbiota-SCFAs axis
JP2021518439A (ja) 微生物組成物の新たな使用
JP2024525794A (ja) 新生児の治療におけるラクトバチルス・パラカゼイ（Ｌａｃｔｏｂａｃｉｌｌｕｓ ｐａｒａｃａｓｅｉ）菌株の使用
JP2024525794A5 (fr)
Lee et al. Lactobacillus reuteri ATG-F4 alleviates chronic stress-induced anhedonia by modulating the prefrontal serotonergic system
Chen et al. Prophylactic effects of supplementation of a combination of Lactobacillus lactis WHH2078 and saffron on depressive‐like behaviors in mice exposed to chronic stress
TW202116333A (zh) 包含細菌品系之組成物
Upreti et al. Microbiota and nutrition as risk and resiliency factors following prenatal alcohol exposure
WO2022192854A1 (fr) Méthodes d'induction de bioptérine et de métabolites apparentés
WO2026044228A1 (fr) Compositions de métabolites de la voie biologique du chorismate de et leurs méthodes d'utilisation
US20250034656A1 (en) Methods for monitoring impact of microbiota transfer therapy in autism spectrum disorder (asd)
Yan et al. Gut Microbiota and bipolar disorder: advances in translational applications
Liao et al. Ligilactobacillus murinus alleviates binge-eating behavior by restoring serotonin metabolism

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25857782

Country of ref document: EP

Kind code of ref document: A1